El Cerrito, CA, United States of America

Meike Visel

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 6.3

ph-index = 6

Forward Citations = 233(Granted Patents)


Company Filing History:


Years Active: 2015-2023

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Inventor Meike Visel in Gene Therapy**

Introduction

Meike Visel is a distinguished inventor based in El Cerrito, California, who has made significant contributions to the field of gene therapy, particularly in the development of adeno-associated virus (AAV) technology. With a total of 11 patents to her name, Visel's innovations are at the forefront of advancing therapeutic methods for ocular diseases.

Latest Patents

Among her latest patents is a groundbreaking disclosure related to adeno-associated virus virions with variant capsid. The patent focuses on AAV virions featuring altered capsid proteins, which demonstrate enhanced infectivity of retinal cells compared to their wild-type counterparts. This advancement opens up new avenues for gene delivery methods to retinal cells in individuals and presents novel approaches to treat ocular diseases.

Career Highlights

Meike Visel has worked with reputable institutions that include the University of California and the University of Pennsylvania. Her academic affiliations have provided a robust platform for her research and innovations, contributing to her impressive portfolio of patents and publications.

Collaborations

Throughout her career, Meike has collaborated with notable professionals such as John G Flannery and David V Schaffer. These collaborations have allowed her to enhance her research efforts, resulting in innovative solutions aimed at addressing complex biomedical challenges.

Conclusion

Meike Visel stands out as an influential figure in the realm of gene therapy. Her pioneering work with adeno-associated virus technology showcases her commitment to advancing medical science and improving treatment options for those affected by ocular diseases. As she continues to innovate, the impact of her contributions will be felt in both clinical settings and the broader scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…